Cortex’s Post

🧠 Raising GBM awareness on #GBMDay. Introducing the FRONTIER study: a feasibility study investigating Y-90 targeted radiation for patients with recurrent GBM. This trial assesses the safety and feasibility of treating GBM with radioembolization. Watch: https://lnkd.in/eUmadY2E Dan Chase Franco Basarabescu, MBA Boston Scientific Peripheral Interventions #GBM #Glioblastoma #GlioblastomaAwarenessDay #BTSM

For 30 years, Hytest has been at the forefront of cardiac troponin research, and we remain dedicated to scientific excellence in this field 🫀 🧑🔬 In our new study, we investigated the influence of heparin on the immunodetection of human cardiac troponins. 🔍 There is conflicting data regarding the effects of heparin on the measurement of cardiac isoforms of troponin I (cTnI) and troponin T (cTnT), which are used for the immunodiagnosis of acute myocardial infarction. 💡 The study concluded that heparin binds to the ITC-complex via cTnT, interacting with several sites on the N-terminal and/or central parts of the cTnT molecule, which might influence the immunodetection of analytes in human blood. Read more: https://lnkd.in/dycRf8xP #IVD #CardiacTroponin #heparin #AMI

🌎🔬 Don’t Miss AMRA Medical at ICFSR 2024! 🔬🌎 This week, the AMRA Medical team will be in attendance at the 14th annual International Conference on Frailty and Sarcopenia Research (ICFSR), where our scientists will be showcasing their latest insights into muscle composition's critical role in various health outcomes. The presentations demonstrate the utility of AMRA's MRI-based body composition analysis platform, AMRA® Researcher, in delivering novel biomarkers that describe overall muscle health. This innovative approach is transforming muscle composition research by enabling more personalized insights on function and performance. By advancing disease research in neuromuscular, metabolic diseases, and beyond, AMRA Medical continues to lead with cutting-edge MRI-powered analyses, offering more personalized insights for researchers, patients, and providers alike. Stay tuned for more updates on how we're advancing disease research with our precision imaging platform in sarcopenia and beyond! To get in touch or if you are attending and want to meet us at ICFSR, reach out to info@amramedical.com. #ICFSR2024 #AMRAMedical #MuscleComposition #ChronicKidneyDisease #Sarcopenia #precisionmedicine #neuromusculardisease #MRI #clinicalresearch

This zero-contrast TAVI case is yet another example where a capture-and-remove embolic filter is a must. Patients with advanced kidney disease cannot risk further damage from the use of contrast and from embolic debris flowing to the kidneys. Every single TAVI procedure produces a shower of debris that flow to the brain, kidneys and lower body.

Dr. Anup Kasi will be presenting at the Visceral Medicine Conference in Leipzig, Germany on Oct. 4. This will be the first presentation of misetionamide (GP-2250) clinical results diving deeper into its Phase 1 trial to evaluate the safety, tolerability, and preliminary efficacy of misetionamide in advanced pancreatic adenocarcinoma. Learn more here: https://lnkd.in/e3CBgtRr #visceralmedicineconference #pancreaticcancer #pancreaticadenocarcinoma

🚀 Milestone Achieved in the SOPRANO CD Trial! 🚀 KCE Trials is happy to announce that the SOPRANO CD study (KCE20-1262) has reached 25% patient recruitment. This is a critical trial aimed at preventing postoperative endoscopic disease recurrence in Crohn's disease. With this prospective, randomized, parallel group, pragmatic trial, the team will evaluate if endoscopy-driven introduction of biological therapy is as efficacious as systematic prophylactic therapy in order to prevent postoperative endoscopic recurrence at week 86 in patients with CD undergoing an ileocolonic resection. Secondary analyses will include influence on clinical and surgical CD recurrence, serious adverse events, costs, work productivity, and quality of life. Congratulations to the dedicated team of Prof. Dr. Ferrante at UZ Leuven and all 29 participating sites (mainly in Belgium) ! And special thanks to patients who have accepted to be part of this trial. #KCETrials #publicfunder #CrohnsDisease #ClinicalResearch #PatientCare #SOPRANOStudy For more information: - KCETrials study website : https://lnkd.in/eDgq7B4f - SOPRANO CD study website: https://lnkd.in/ekaYG56N

At #EuroPCR, Prof. Shanshan Zhou from 301 Hospital, announced the primary outcome of randomized controlled trial of the safety and effectiveness for OCT or IVUS-guide (TARGET 3C Trial). The results showed that In-Stent Late Loss (mm) @13mo: OCT (0.21±0.30) vs IVUS (0.26±0.30) P=0.1394, OCT (0.21±0.30) vs Angio (0.31±0.41) P=0.0383. TLF @12mon: OCT vs IVUS (4.9% vs 4.0%, P>0.9999), OCT vs Angio (4.9% vs 7.2%, P=0.8807). Stent Thrombosis rate @12mo is 0! Mean neo-intimal thickness(μm) @3mo: OCT (47.8±22.4) vs IVUS (52.6±36.24) P>0.9999, OCT (47.8±22.4) vs Angio (61.5±27.08) P=0.1230. The study results showed early rapid healing of the #Firehawk® stent in moderate-to-severely complex calcified coronary lesion regardless of whether guided by OCT, IVUS, or angiography. #TARGET3C #Coronary #OCT #IVUS #Angiography

Advances in new treatments, innovative research and OCT technology—like Heidelberg Engineering’s ANTERION®—are contributing to earlier detection of glaucoma. The Heidelberg Engineering team will be at Booth #23 at APGC 2024 in Manila, Philippines, from May 24-26 with their glaucoma toolkit—so stop by and see for yourself how you can optimize glaucomatous disease diagnosis, improve clinical workflow and effectively manage patients! SPECTRALIS® Glaucoma Module Premium Edition provides clinicians with a comprehensive set of tools for the assessment of structural loss that is characteristic of glaucoma—while ANTERION® supports with anterior segment OCT images for precise measurements that provide valuable diagnostic insights for glaucoma specialists. UNCOVER MORE:  https://lnkd.in/e3MPtrCw https://lnkd.in/dbuS8mN See you at APGC 2024! #glaucoma #SPECTRALIS #ANTERION #APGC #MediaMICE

3 things I learned at the MR-Linac Consortium meeting in Singapore: 1.Iron-corrected T1 mapping (cT1) is a non-contrast MR sequence that assesses liver fibrosis. It could aid functional liver-sparing planning, particularly in PULSAR approaches for HCC. (Shout out The Christie NHS Foundation Trust) 2.Large-volume brain metastases from NSCLC can shrink dramatically during hypofractionated RT and is another great indication for adaptive MRgRT. (Shout out CAMS in Beijing) 3.DWI/ADC kinetics show great potential as a biomarker to identify both who and where early GBM recurs after RT (shoutout Sunnybrook)

💡 Do you know what Public Procurement of Innovation (PPI) is? 🎬 Watch Episode 2 of RaDAR Collab to find out how #PPI can make a difference in the fight against #AMR! 🦠